These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 30460933)

  • 1. Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer.
    Rhea LP; Gupta B; Aragon-Ching JB
    Asian J Androl; 2019; 21(2):107-108. PubMed ID: 30460933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
    Penson DF; Armstrong AJ; Concepcion R; Agarwal N; Olsson C; Karsh L; Dunshee C; Wang F; Wu K; Krivoshik A; Phung D; Higano CS
    J Clin Oncol; 2016 Jun; 34(18):2098-106. PubMed ID: 26811535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utility of novel androgen receptor therapies in the real world: A nuanced approach.
    Dhawan M; Ryan CJ
    Urol Oncol; 2016 Aug; 34(8):340-7. PubMed ID: 27450893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: a retrospective study.
    Iguchi T; Tamada S; Kato M; Yasuda S; Otoshi T; Hamada K; Yamasaki T; Nakatani T
    Int J Clin Oncol; 2019 Jul; 24(7):848-856. PubMed ID: 30741370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzalutamide: a novel anti-androgen with prolonged survival rate in CRPC patients.
    Dhingra R; Sharma T; Singh S; Sharma S; Tomar P; Malhotra M; Bhardwaj TR
    Mini Rev Med Chem; 2013 Aug; 13(10):1475-86. PubMed ID: 23701654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    Rodriguez-Vida A; Galazi M; Rudman S; Chowdhury S; Sternberg CN
    Drug Des Devel Ther; 2015; 9():3325-39. PubMed ID: 26170619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
    Taneja SS
    J Urol; 2020 Nov; 204(5):1097-1098. PubMed ID: 32897151
    [No Abstract]   [Full Text] [Related]  

  • 8. Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide.
    Wallis CJD; Chandrasekar T; Goldberg H; Klotz L; Fleshner N; Satkunasivam R; Klaassen Z
    Eur Urol Oncol; 2018 Aug; 1(3):238-241. PubMed ID: 31102627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Combination of Enzalutamide and Opioids: A Painful Pitfall?
    Benoist GE; van Oort IM; Burger DM; Koch BCP; Mehra N; van Erp NP
    Eur Urol; 2019 Feb; 75(2):351-352. PubMed ID: 30245086
    [No Abstract]   [Full Text] [Related]  

  • 10. Enzalutamide and metastasis risk in prostate cancer.
    Gourd E
    Lancet Oncol; 2018 Aug; 19(8):e387. PubMed ID: 29983344
    [No Abstract]   [Full Text] [Related]  

  • 11. [Enzalutamide-new option in metastatic castration-sensitive prostate cancer? : Preliminary results of a randomized phase III trial (ENZAMET)].
    Boegemann M
    Urologe A; 2020 Jan; 59(1):78-79. PubMed ID: 31853892
    [No Abstract]   [Full Text] [Related]  

  • 12. Enzalutamide in castration-resistant prostate cancer.
    Burki TK
    Lancet Oncol; 2014 Jul; 15(8):e312. PubMed ID: 25121180
    [No Abstract]   [Full Text] [Related]  

  • 13. Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer.
    Zhang T; Zhu J; George DJ; Armstrong AJ
    Expert Opin Pharmacother; 2015 Mar; 16(4):473-85. PubMed ID: 25534660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications?
    Arslan C
    World J Urol; 2017 Mar; 35(3):479-480. PubMed ID: 27417948
    [No Abstract]   [Full Text] [Related]  

  • 15. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy.
    Tombal B
    Eur Urol; 2015 Aug; 68(2):236-7. PubMed ID: 24908474
    [No Abstract]   [Full Text] [Related]  

  • 17. Resistance emerges to second-generation antiandrogens in prostate cancer.
    Nelson WG; Yegnasubramanian S
    Cancer Discov; 2013 Sep; 3(9):971-4. PubMed ID: 24019330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzalutamide for the treatment of prostate cancer: results and implications of the AFFIRM trial.
    Nadal R; Taplin ME; Bellmunt J
    Future Oncol; 2014 Feb; 10(3):351-62. PubMed ID: 24559444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer.
    Sternberg CN
    Future Oncol; 2019 May; 15(13):1437-1457. PubMed ID: 30848157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case report of enzalutamide administration in a dialysis-dependent patient with castration-resistant prostate cancer.
    Tsang ES; de Haan M; Eigl BJ
    J Oncol Pharm Pract; 2018 Mar; 24(2):143-145. PubMed ID: 28147927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.